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Very Important Paper

Enantiomerically Pure Quinoline-Based k-Opioid Receptor
Agonists: Chemoenzymatic Synthesis and Pharmacological
Evaluation
Benedikt Martin,[a] Dirk Schepmann,[a] Freddy A. Bernal,[b] Thomas J. Schmidt,[b] Tao Che,[c]
Karin Loser,[d, e] and Bernhard Wünsch*[a, e]
Racemic K-opioid receptor (KOR) agonist 2-(3,4-dichlorophenyl)1-[(4aRS,8SR,8aSR)-8-(pyrrolidin-1-yl)-3,4,4a,5,6,7,8,8a-octahydroquinolin-1(2H)-yl]ethan-1-one ((�)-4) was prepared in a diastereoselective synthesis. The first key step of the synthesis was the
diastereoselective hydrogenation of the silyl ether of 1,2,3,4tetrahydroquinoin-8-ol ((�)-9) to afford cis,cis-configured perhydroquinoline derivative (�)-10. Removal of the TBDMS protecting group led to a β-aminoalcohol that reacted with SO2Cl2 to
form an oxathiazolidine. Nucleophilic substitution with pyrrolidine resulted in the desired cis,trans-configured perhydroquinoline upon inversion of the configuration. In order to obtain
enantiomerically pure KOR agonists 4 (99.8 % ee) and ent-4
(99.0 % ee), 1,2,3,4-tetrahydroquinolin-8-ols (R)-8 (99.1 % ee) and
(S)-8 (98.4 % ee) were resolved by an enantioselective acetylation catalyzed by Amano lipase PS-IM. The absolute config-

uration was determined by CD spectroscopy. The 4aR,8S,8aSconfigured enantiomer 4 showed sub-nanomolar KOR affinity
(Ki = 0.81 nM), which is more than 200 times higher than the
KOR affinity of its enantiomer ent-4. In the cAMP assay and the
Tango β-arrestin-2 recruitment assay, 4 behaved as a KOR
agonist. Upon incubation of human macrophages, human
dendritic cells, and mouse myeloid immune cells with 4, the
number of cells expressing co-stimulatory receptor CD86 and
proinflammatory cytokines interleukin 6 and tumor necrosis
factor α was significantly reduced; this indicates the strong antiinflammatory activity of 4. The anti-inflammatory effects
correlated well with the KOR affinity: (4aR,8S,8aS)-4 was slightly
more potent than the racemic mixture (�)-4, and the distomer
ent-4 was almost inactive.

1. Introduction
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The group of opioid receptors consists of four subtypes. They
are termed according to their prototypical agonists μ-opioid
receptor (MOR, morphine), k-opioid receptor (KOR, ketocyclazocine) and opioid receptor-like 1 (ORL1) receptor (NOR, nociceptine) or according to the tissue, in which the receptor was
detected first, δ-opioid receptor (DOR, vas deferens).[1] Initially,
the σ receptor was considered as an additional opioid receptor
subtype, but this classification was later corrected and the σ
receptor was reclassified as non-opioid receptor type.[1] All
opioid receptors belong to the class A (rhodopsin-like) γ
subfamily of G protein-coupled receptors (GPCRs).[2] They share
a common seven-transmembrane architecture and are coupled
predominantly to heterotrimeric Gi/Go proteins. Cloning of the
four opioid receptors revealed a homology of more than 60 %
with respect to their amino acid sequences.[3]
Activation of MOR, KOR and DOR leads to strong analgesia,
but also to subtype specific side effects.[4] Most of the clinically
used analgesics are MOR agonists, such as morphine and
methadone, which cause euphoria, constipation, respiratory
depression, development of tolerance and addiction side
effects.[5] In contrast, KOR agonists do not elicit these typical
MOR-mediated side effects. Therefore, KOR represents an
interesting target for the development of safer analgesics.[5]
However, KOR agonists are not devoid of side effects, since they
induce centrally mediated dysphoria, sedation, and diuresis.[6] A
high density of KOR is not only found in the central nervous
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system, but also in peripheral cells (e. g., immune cells, including
T cells and antigen presenting cells)[4] and peripheral tissues
(e. g., skin). KOR agonists are also of interest for the treatment of
itching skin diseases, including pruritus, atopic dermatitis and
psoriasis. In Japan, the morphinane derivative nalfurafine
activating KOR in the sub-nanomolar range (Ki = 0.17 nM)[7] is
approved for the treatment of uremic pruritus. Its antipruritic
activity is linked to activation of peripheral KOR.[8]
In a very recent study, the pharmacological effects of the
prototypical KOR agonist U-50,488 (1, Ki = 0.34 nM, Figure 1)[9] in
experimental autoimmune encephalomyelitis (EAE) were investigated. EAE is a commonly used animal model of multiple
sclerosis (MS). KOR activation by U-50,488 (1) alleviated the
symptoms of EAE by preventing neuronal damage and
promoting remyelination.[10] The anti-inflammatory properties of
KOR agonists are mainly based on the downregulation of cell
proliferation and the inhibition of immune cell activation, which
leads to a reduced secretion of proinflammatory cytokines.[11]
Very recently, we have shown that the KOR agonist (�)-2 (Ki =
5.6 nM, EC50 = 2.8 nM, Figure 1), which we successfully synthesized according to a diastereoselective pathway, significantly
decreased the expression of classical activation markers as well
as interferon-gamma (IFN-γ), tumor-necrosis-factor-alpha (TNFα), and interleukin 17 A (IL-17 A). In parallel, the compound
increased the release of anti-inflammatory cytokines like IL-10
in different mouse and human immune cell subsets pointing to
an immunomodulatory effect of (�)-2. In support of this, (�)-2
significantly reduced disease perpetuation in EAE. Experiments
in KOR deficient mouse mutants confirmed that the observed
beneficial effects of (�)-2 were indeed mediated by binding of
the compound to KOR.[12]
The known KOR agonists belong to four structurally diverse
classes of compounds: peptides derived from the endogenous
KOR agonist dynorphin A,[13] morphinoids,[14] the non-basic
natural product salvinorin A,[15] and ethylenediamines with U50,488 (1)[16] being the first synthetic KOR agonist. Whereas one
N-atom of the ethylenediamine-based KOR agonists should be
connected with a (3,4-dichlorophenyl)acetyl moiety, the second
N-atom should display basic properties. Usually, this N-atom is
part of a pyrrolidine ring, which after protonation forms a
crucial ionic interaction with Asp138 in the KOR binding site.[17]
The (3,4-dichlorophenyl)acetyl moiety at the other end of the
ethylenediamine pharmacophore interacts with a hydrophobic
pocket of KOR.
Recently, we have reported a series of conformationally
constrained KOR agonists, in which the cyclohexane ring of U-

Figure 1. Important ethylenediamine-based KOR agonists. # Only one
enantiomer of racemic mixtures (�)-2 and (�)-4 is shown.
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50,488 (1) is embedded in a perhydroquinoxaline scaffold.[18,19]
A very high KOR affinity (Ki = 0.25 nM, EC50 = 2.0 nM) was found
for the 4aR,5S,8aS-configured perhydroquinoxaline 3 with a cisconfigured bicyclic ring system.[18] (Figure 1) This result is in
good accordance with the results of a patent describing
racemic KOR agonists with a perhydroquinoline framework. In
this series of compounds, the highest KOR affinity was found
for racemic (�)-4 (IC50 = 2.7 nM) with a cis-configured bicyclic
framework and trans-oriented pyrrolidinyl moiety (IC50 = 2.7 nM;
Figure 1).[20] As the Ki value of the KOR agonist (�)-4 was not
reported in the patent, a direct comparison of the KOR affinity
of enantiomerically pure 3 and racemic (�)-4 was not possible.
In the patent, the racemic KOR agonist (�)-4 was obtained
by a non-stereoselective synthesis and subsequent laborious
and time-consuming separation of racemic diastereomers. In
this manuscript we would like to report an efficient diastereoselective synthesis of (�)-4. A chemoenzymatic route should
provide enantiomerically pure KOR agonists 4 and ent-4, which
will be thoroughly characterized in various biological assays.

Results and Discussion
Diastereoselective synthesis of racemic (�)-4
The diastereoselective synthesis of cis,trans-configured racemic
KOR agonist (�)-4 started with 5,6,7,8-tetrahydroquinoline (5),
which was oxidized with m-chloroperoxybenzoic acid (mCPBA)
to afford the N-oxide 6 (Scheme 1). Boekelheide
rearrangement[21] of N-oxide 6 was performed with Ac2O at
120 °C providing the acetate (�)-7. After hydrolysis of acetate
(�)-7 with NaOH, the alcohol (�)-8 was protected with a silyl
group to give silyl ether (�)-9. The bulky tert-butyldimethylsilyl
protective group was chosen, since it should direct the hydrogenation of the aromatic pyridine ring from the opposite side.
Thus, hydrogenation (5 bar) of (�)-9 in the presence of catalyst
Rh/Al2O3 in the solvent HOAc afforded diastereoselectively the
cis,cis-configured perhydroquinoline (�)-10 in 94 % yield.[22] In
addition to the control of the stereoselectivity, the silyl
protective group should be stable during the hydrogenation
conditions in pure HOAc used as solvent, which activates the
pyridine ring and accelerates its hydrogenation[23] providing
increased yields of (�)-10. The hydrogenation represents the
key step in the nine-step reaction sequence, since it establishes
the configuration of all three centers of chirality with excellent
diastereoselectivity.
The relative configuration of (�)-10 was determined by
nuclear Overhauser effect. (Figure 2) Irradiation at the resonance frequency of 8a-H (δ = 2.85 ppm, t, J = 3.5 Hz) led to
increased signals of 2-Haxial (δ = 2.59 ppm), 4a-H/7-Haxial (δ =
1.64 ppm) and 8-Haxial (δ = 3.27 ppm) in the recorded NOE
difference spectrum. Additional interactions between 6-Haxial
(δ = 1.31 ppm) and 8-H (δ = 3.27 ppm) were observed in a twodimensional NOESY spectrum. Both spectra are shown in the
supporting information. These NOEs clearly prove the cisorientation of the protons 4a-H, 8a-H and 8-Haxial, which
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Scheme 1. Synthesis of racemic KOR agonist (�)-4. a) mCPBA, CH2Cl2, RT, 19 h, 81 %; b) (Ac)2O, 120 °C, 1 h, 88 %; c) aqu NaOH 1 M, CH3OH, RT, 1 h, 98 %; d)
TBDMSCl, imidazole, DMF, RT, 16 h, 63 %; e) H2 (5 bar), Rh/Al2O3, AcOH, RT, 25 h, 94 %; f) TBAF, THF, RT, 18 h, 88 %; g) SO2Cl2, triethylamine, CH2Cl2, 0 °C!RT,
20 h, 34 %; h) pyrrolidine, CH3CN, 80 °C, 18 h, 82 %; i) 2-(3,4-dichlorophenyl)acetyl chloride, ethyldi(isopropyl)amine, CH2Cl2, RT, 1 h, 56 %. Only one enantiomer
of the racemic mixtures is shown.

Figure 2. Neighborhood of protons of cis,cis-configured perhydroquinoline
(�)-10 determined by nuclear Overhauser effect (NOE).

unequivocally confirms the cis,cis-configuration of the perhydroquinoline ring of (�)-10.
The TBDMS protective group of (�)-10 was removed with
tetrabutylammonium fluoride (TBAF) to yield β-aminoalcohol
(�)-11, which was treated with SO2Cl2 to give oxathiazolidine
(�)-12 in 34 % yield. In the cyclic sulfuric ester amide (�)-12 the
original OH moiety of the β-aminoalcohol (�)-11 was activated
for a SN2 reaction and the secondary amino moiety was
protected. The nucleophilic substitution was carried out with
pyrrolidine giving the diamine (�)-13 upon removal of the Nprotective group during work-up under acidic conditions. This
SN2 reaction of (�)-12 represents the second key step, as the
inversion of the configuration at C-8 during the nucleophilic
attack led to the desired cis,trans-configured perhydroquinoline
system. Finally, the secondary amine (�)-13 was acylated with
2-(3,4-dichlorophenyl)acetyl chloride to afford the racemic KOR
agonist (�)-4.

Chemoenzymatic synthesis of enantiomerically pure KOR
agonists 4 and ent-4
A lipase-catalyzed kinetic resolution of racemic alcohol (�)-8
was planned as key step for the synthesis of the enantiomerically pure KOR agonists 4 and ent-4. In a previous study, the
ChemMedChem 2020, 15, 1408 – 1420
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lipase-catalyzed kinetic resolution of alcohol (�)-8 had been
carried out using Candida antarctica lipase as biocatalyst and
vinyl acetate as acetylating reagent at 60 °C for 30 h.[24] Under
these conditions the acetate (R)-7 and the alcohol (S)-8 were
obtained in 43 % and 44 % yield, respectively, with an enantiomeric purity > 99 % ee in both cases.
Herein, Amano lipase PS-IM was used for the kinetic
resolution of racemic alcohol (�)-8, which allowed milder
reaction conditions, that is, reaction at room temperature, a
longer reaction time, and isopropenyl acetate as acetylating
agent. (Figure 3A) Although alcohol (S)-8 (97.9 % ee) and acetate
(R)-7 (97.3 % ee) were present in the ratio 50 : 50 after a reaction
time of 70 h (Figure 3B and C), excellent enantiomeric purity of
remaining alcohol (S)-8 (98.4 % ee) was obtained after a very
long reaction time of 140 h. (Figure 3C) As expected, the Amano
lipase PS-IM acetylated almost exclusively the R-configured
alcohol (R)-8. Thus, a long reaction time led to conversion of
even traces of alcohol (R)-8 into acetate (R)-7 providing
excellent enantiomeric excess of the remaining alcohol (S)-8. On
the other hand, small amounts of alcohol (S)-8 were also
acetylated by the lipase resulting in decreased enantiomeric
purity of the acetate (R)-7. After a reaction period of 140 h,
acetate (R)-7 (96.2 % ee) and alcohol (S)-8 (98.4 % ee) were
isolated in 45 and 32 % yield, respectively. Chiral HPLC of (S)-8 is
shown in Figure S2 in the Supporting Information.
In order to increase the enantiomeric purity of R-configured
alcohol (R)-8, acetate (R)-7 (96.2 % ee) was hydrolyzed with
NaOH and the resulting alcohol (R)-8 (94.0 % ee) was used in a
second lipase-catalyzed acetylation reaction (Figure 4). As the
lipase converted predominantly the R-configured alcohol (R)-8
into its acetate (R)-7 (Figure 4A), the amount of (R)-8 decreased
rapidly as the reaction proceeded (Figure 4B). However, the
enantiomeric purity of the acetate (R)-7 was very high from the
beginning. After a reaction period of 52 h, the transformation
was stopped, and the acetate (R)-7 was obtained in 88 % yield
and 99.5 % ee (Figure 4C). Finally, alcohol (R)-8 (99.1 % ee) was
obtained by ester cleavage with NaOH (Figure S3).
Interestingly, the ee value of the R-configured alcohol (R)-8
decreased continuously until it reached a minimum (< 5 %ee)
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Figure 3. Lipase-catalyzed kinetic resolution of racemic alcohol (�)-8. A) Enantioselective acetylation of (�)-8 by using isopropenyl acetate in the presence of
Amano lipase PS-IM. B) Amounts [%] of remaining alcohol 8 and formed acetate 7 during the reaction period. C) Time course of the ee values of alcohol (S)-8
and acetate (R)-7 during the transformation.

Figure 4. Saponification and second lipase-catalyzed acetylation of enantiomerically enriched alcohol (R)-8 (94.0 % ee). A) Transformations of (R)-7 (96.2 % ee).
B) Amounts [%] of remaining alcohol 8 and formed acetate 7 during the reaction period. C) Development of the ee values of alcohols (R)-8/(S)-8 and acetate
(R)-7 during the transformation. The decreased ee value of acetate (R)-7 at the beginning of the transformation is due to very small amounts of acetate 7
(0.04 %) in the starting material (R)-8.

after 32 h. At this time point the amounts of desired (R)- and
undesired S-configured alcohols (R)-8 and (S)-8 are almost
identical. After passing the minimum, ee values for S-configured
alcohol (S)-8 increased, as (R)-8 was transformed selectively.

ChemMedChem 2020, 15, 1408 – 1420
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In order to determine the absolute configuration of the
enantiomeric alcohols (R)-8 and (S)-8, CD spectra of the
corresponding enantiomeric silyl ethers (R)-9 and (S)-9 were
recorded in acetonitrile (Figure 5) Time-dependent density
functional theory (TDDFT) calculation at the B3LYP/6-31G(d,p)
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With both enantiomerically pure alcohols (R)-8 (99.1 % ee)
and (S)-8 (98.4 % ee) in hand, the synthetic route already
described (Scheme 1) was performed in order to obtain the
KOR agonists 4 (4aR,8S,8aS configuration) and ent-4 (4aS,8R,8aR
configuration). The corresponding reaction scheme is shown in
Scheme S1. The final control of the enantiomeric purity showed
some racemization of both enantiomers (4: 80.3 % ee, ent-4:
66.3 % ee). We assume that partial racemization occurred during
hydrogenation of the TBDMS ethers (R)-9 and (S)-9 under acidic
conditions. Therefore, additional purification of the enantiomers
4 and ent-4 by chiral preparative HPLC using a Chiralpak® IA
column was performed resulting in enantiomerically pure KOR
agonists 4 (99.8 % ee) and ent-4 (99.0 % ee).

Figure 5. Recorded CD spectra of enantiomeric TBDMS ethers (R)-9 and (S)-9
and TDDFT calculated CD spectrum of S-configured TMS-ether (S)-14 as
model compound.

level were used to correlate the observed Cotton effects with
the corresponding absolute configuration. The trimethylsilyl
ether (S)-14 was employed as model compound due its
significantly higher conformational restrictions compared to (R)9 and (S)-9 (but bearing the same chromophore), which
translated in lower overall computational costs. As a result, the
absolute configuration of both silyl ethers (R)-9 and (S)-9 was
unequivocally assigned. (Figure 5) This configurational assignment perfectly agrees with the observation that Amano lipase
PS-IM preferably acetylates R-configured secondary alcohols (in
case the larger substituent has higher CIP priority than the
smaller substituent).[24]

KOR affinity, selectivity and agonistic activity
The KOR affinity of the synthesized quinoline derivatives and
some reference compounds was investigated in competitive
radioligand receptor binding assays using guinea pig brain
homogenates as source of KOR and [3H]U-69,593 as competitive
radioligand.[25–27] Table 1 summarizes the affinity data of perhydroquinolines, related perhydroquinoxalines and reference
compounds.
The KOR affinity of racemic (�)-4 (Ki = 1.2 nM) is approximately five times higher than the KOR affinity of triazole-based
KOR agonist (�)-2, but five times lower than those of
enantiomerically pure methyl carbamate 3. The KOR affinity of
(�)-4 resides almost exclusively in the 4aR,8S,8aS-configured
enantiomer 4 (Ki = 0.81 nM), which is more than 200-fold more
active than the distomer ent-4. The Ki value of the eutomer 4 is
in the same range as the Ki values of the prototypical KOR
agonists U-50,488 and the methyl carbamate 3. (Table 1)

Table 1. Affinities of racemic and enantiomerically pure perhydroquinolines and reference compounds for KOR and related receptors.

Compd.

(�)-2[12]
3[19]
(�)-4
4
ent-4
U-50,488
naloxone
morphine
SNC80
(+)-pentazocine
haloperidol

Configuration

racemate
racemate
4aR,8S,8aS
4aS,8R,8aR
1S,2S

Ki � SEM [nM] [a,b]
KOR
[3H]U-69,593

MOR
[3H]DAMGO

DOR
[3H]DPDPE

σ1
[3H](+)-pentazocine

σ2
[3H]DTG

5.6 � 0.6
0.25 � 0.08
1.2 � 0.6
0.81 � 0.32
195 � 67
0.34 � 0.07
7.3 � 0.40
–
–
–
–

573
43 � 9.2
1200
0%
0%
–
2.3 � 1.1
5.2 � 1.6
–
–
–

413
58 � 8.4
1400
0%
0%
–
103
–
1.2 � 0.5
–
–

2%
0%
0%
676
0%
–
–
–
–
5.4 � 0.5
6.6 � 0.9

0%
8%
0%
3300
12 %
–
–
–
–
–
78 � 2.3

[a] A value in % reflects the inhibition of the radioligand binding at a test compound concentration of 1 μM. Ki values without SEM values represent the mean
of two experiments (n = 2) and Ki values with SEM values represent the mean of three experiments (n = 3). [b] Guinea pig brain membrane preparations were
used in the KOR, MOR and σ1 assay. In the DOR assay rat brain and in the σ2 assay rat liver membrane preparations were used.
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The enantiomerically pure KOR agonist 4 as well as the
racemic mixture (�)-4 and the distomer ent-4 showed very low
affinity towards MOR and DOR, indicating high selectivity for
KOR over the other two opioid receptor subtypes MOR and
DOR. Due to the historical and ligand structure relationship of σ
and opioid receptors, in particular KOR, σ1 and σ2 receptor
affinity of the ligands were also recorded.[28] Very low σ1 and σ2
affinity was found for the 4aR,8S,8aS-configured enantiomer 4.
However, the Ki values at both σ receptors indicate a more than
800- (σ1) and more than 4000-fold (σ2) selectivity for KOR.
The KOR agonistic activity was investigated for the eutomer
4 with 4aR,8S,8aS configuration. For this purpose, two assays
recording the reduction of cAMP production (human HEK293T
cells) and β-arrestin-2 recruitment (Tango assay using human
HTLA cells) were performed (Table 2).
In Table 2, the KOR affinity and agonistic activity of
enantiomerically pure 4 and the prototypical KOR agonist U50,488 are compared. Whereas the KOR affinity of 4 is slightly
lower than the KOR affinity of U-50,488, its effect on the cAMP
production is higher than that of U-50,488. With an EC50 value
of 0.029 nM 4 shows very high KOR agonistic activity. In the βarrestin-2 recruitment assay 4 is also approximately seven times
more active than U-50,488. In the cAMP assay 4 reaches the
same total effect as U-50,488 (100 % intrinsic activity), whereas
in the β-arrestin-2 recruitment assay 4 attains only 64 % of the
U-50,488 effect. These data indicate, that 4 does not prefer the
activation of one of the two pathways (no biased activation).
In analogous MOR and DOR cAMP and β-arretin-2 recruitment assays, 4 did not exhibit significant activity, indicating the
selective activation of these pathways via interaction with KOR.

Effects of KOR agonists (�)-4 and its enantiomers 4 and
ent-4 on immune cells
To further characterize the anti-inflammatory and immunomodulatory properties of the newly synthesized compounds different immune cell subsets were isolated including T cells,
dendritic cells (DC) or macrophages, which are known to be
involved in the development and progression of various
(systemic) inflammatory disorders.[29] Immune cell populations

Table 2. Correlation of KOR affinity and KOR activity of 4 and U-50,488.

Compd.

4
U-50,488

KOR[a]
[3H]U-69,593
Ki � SEM
[nM]

cAMP[b]

β-Arrestin-2[c]

EC50 [nM]

Emax [%][d]

EC50 [nM]

Emax [%][d]

0.81 � 0.32
0.34 � 0.07

0.029
0.16

103
100

1.09
7.85

64
100

[a] Guinea pig brain membrane preparations. [b] Human HEK 293T cells. [c]
Human HTLA cells. [d] The Emax values refer to U-50,488 (100 %).
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were purified from lymph nodes and spleen of wild-type (WT)
mice or from peripheral blood of healthy human donors,
stimulated with lipopolysaccharide (LPS; myeloid cells) or antiCD3 plus anti-CD28 (T cells) to upregulate the expression of
typical activation markers and induce the production of proinflammatory cytokines. Upon activation, antigen-presenting
cells, such as DC or macrophages, upregulate co-stimulatory
markers of the tumor-necrosis factor (TNF) or B7 families
including CD40 or CD86, respectively and start to secrete INF-γ,
IL-6, IL-12 or TNF-α. In systemic inflammation, these activated
antigen-presenting cells get into direct contact to naive T cells,
resulting in the priming of effector T cells (T helper or cytotoxic
T cells). Effector T cells including Th1 or Th17 cells migrate to
the site of inflammation and thus, can be found in target
organs. Under infectious conditions they are critically involved
in the elimination of bacteria or virus-containing cells. However,
in chronic and complex inflammatory diseases, Th1 and Th17
are also considered to mediate tissue destruction as shown in
psoriasis, atopic dermatitis, rheumatoid arthritis or multiple
sclerosis.[30]
To assess the anti-inflammatory capacity of the KOR
agonists (�)-4, 4 and ent-4 pre-activated T cells, macrophages,
neutrophils and DC were stimulated with the KOR agonists in a
concentration of 1 μM after having confirmed that this concentration is sufficient to markedly downregulate the expression of
the early and transient activation marker CD69 (Figure S7).
Interestingly, in activated human macrophages we observed
significantly reduced numbers of cells expressing the costimulatory receptor CD86 as well as the cytokines IL-6 and
TNF-α after stimulation with the compounds (�)-4 and 4
(Figure 6A and B). In contrast, compound ent-4 did not show
anti-inflammatory properties since comparable levels of cells
expressing co-stimulatory receptors or pro-inflammatory cytokines were found in ent-4 stimulated cultures and controls
(Figure 6A and B). Worth mentioning that the potent antiinflammatory effect of (�)-4 and 4 was not limited to human
macrophages since we observed a similar reduction in the
expression of typical surface markers characteristic for cell
activation and classical pro-inflammatory cytokines in human
DC and mouse myeloid immune cell subsets (Figure 6C–F).
It is well known that opioid receptor agonists not only
control the phenotype and function of myeloid cells but also
modulate lymphoid immune cell subsets and thereby, impact
on the innate as well as the adaptive immune system. In line
with this, it has been shown that besides impairing DC
maturation, KOR agonists are able to prevent effector T cell
priming.[12,31]
To assess the effects of the compounds (�)-4, 4 and ent-4
during T cell activation and to characterize their potential antiinflammatory capacity in more detail we purified CD4 + T cells
from peripheral blood of healthy human donors or spleen and
lymph node tissue of WT mice, activated the cells with anti-CD3
plus anti-CD28 and stimulated them with the three KOR
agonists. Notably, the numbers of both, Th1 and Th17 cells
were significantly downregulated in cultures treated with (�)-4
or 4 whereas we did not observe reduced levels of CD4 + T cells
expressing IFN-γ and the transcription factor T-bet (Th1 cells) or
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Figure 6. Compounds (�)-4 and 4 significantly reduced the activation and cytokine production in myeloid human and mouse immune cells. A), B) Human
macrophages were sorted from peripheral blood mononuclear cells (PBMC) by magnetic beads and activated with LPS for 12 h as described (activated
macrophages). Subsequently, cells were stimulated with compounds (�)-4, 4 and ent-4 (1 μM each) for an additional 48 h. Control cells received an equal
amount of PBS. A) Representative dot-plots and B) percentages of cells expressing the pro-inflammatory cytokines TNF-α and IL-6 or the co-stimulatory
surface marker CD86 from n = 4 healthy human donors are shown. Cells are gated for CD11b + CD68 + macrophages, and IL-6 as well as TNF-α staining was
performed after cell permeabilization. Data are presented as mean � SEM; * p < 0.05. C), D) Mouse macrophages were isolated from lymph node and spleen
tissue and stimulated with LPS for 12 h as described (activated macrophages). Subsequently, cells were cultured in the presence of compounds (�)-4, 4 and
ent-4 (1 μM each) for an additional 48 h. Control cells received an equal amount of PBS. C) Representative dot-plots and D) percentages of cells expressing the
pro-inflammatory cytokines TNF-α and IL-6 or the co-stimulatory surface marker CD86 from n = 4 individual mice are shown. Cells are gated for CD11b + F4/
80 + macrophages, and IL-6 as well as TNF-α staining was performed after cell permeabilization. Data are presented as mean � SEM; * p < 0.05. E) Human or F)
mouse dendritic cells were purified from peripheral blood or spleen tissue, respectively, and stimulated with LPS for 12 h. Subsequently, cells were incubated
with compounds (�)-4, 4 and ent-4 (1 μM each) for an additional 48 h or received an equal amount of PBS. Percentages of cells expressing the proinflammatory cytokine IL-12 or the co-stimulatory surface marker CD40 from n = 4 healthy human donors (E) or n = 4 individual mice (F) are shown. Cells are
gated for HLA-DR + (E) or MHC-II + F4/80 CD19 (F) and IL-12 staining was performed after cell permeabilization. Data are presented as mean � SEM; * p < 0.05.

IL-17 and the transcription factor ROR-c (Th17 cells) in T cell
cultures that were stimulated with compound ent-4 (Figure 7A
and B). Of note, the anti-inflammatory effect of compound 4
was even more pronounced compared to (�)-4 and was not
limited to human CD4 + T cells since we observed a similar
reduction of Th1 and Th17 cells in murine cultures (Figure 7D
and E). However, although compound 4 (and to a lesser extend
also compound (�)-4) markedly downregulated the cytokine
secretion and transcription factor expression in activated mouse
and human CD4 + T cells, both compounds did not exhibit
immunomodulatory capacities. Immunomodulation would for
instance, require the switch from activated effector to immunosuppressive regulatory CD4 + T cells (Treg), which among other
markers are characterized by the expression of the transcription
factor Foxp3. Neither compound (�)-4 nor 4 was able to
modulate Foxp3 expression in CD4 + T cells (Figure 7C and F).
Two subsets of Treg are known; thymus-derived Treg (tTreg)
ChemMedChem 2020, 15, 1408 – 1420
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and peripherally induced Treg (pTreg) that can be generated
from conventional CD4 + T cells and are converted in peripheral
tissues to cells that express Foxp3 and acquire suppressive
ability. The transcription factor Helios, a member of the Ikaros
transcription factor family, is believed to be a marker of tTreg.[32]
Therefore, we analyzed the Helios + and Helios Treg subsets
separately in T cell cultures stimulated with the compounds
(�)-4, 4 and ent-4 but did not detect any significant difference
in cell numbers compared to non-stimulated controls (Figure 7C
and F), confirming that (�)-4 and 4 show broad and potent
anti-inflammatory effects but none of the k-agonists seems to
have immunomodulatory properties.
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Figure 7. Compounds (�)-4 and 4 significantly reduced the cytokine production and transcription factor expression in Th1 and Th17 cells but did not exhibit
immunomodulatory capacities. A)–C) Human CD4 + T cells were sorted from peripheral blood and activated with anti-CD3 and anti-CD28 for 48 h (activated
CD4). Subsequently, cells were stimulated with compounds (�)-4, 4 and ent-4 (1 μM each) for an additional 48 h. Control cells received an equal amount of
PBS. A) Representative dot-plots and percentages of cells expressing B) the Th1 markers IFN-γ and T-bet, the Th17 markers IL-17 and ROR-c from n = 4 healthy
human donors or C) the Treg markers Foxp3 and Helios are shown. Cytokine and transcription factor staining were performed after cell permeabilization. Data
are presented as mean � SEM; * p < 0.05. D)–F) Mouse CD4 + T cells were sorted from spleen and lymph node tissue of wild-type mice, activated with anti-CD3
and anti-CD28 for 48 h (activated CD4), and stimulated with compounds (�)-4, 4 and ent-4 (1 μM each) for an additional 48 h. D) Representative dot-plots and
percentages of cells expressing E) the Th1 markers IFN-γ and T-bet, the Th17 markers IL-17 and ROR-γt from n = 4 individual mice or F) the Treg markers
Foxp3 and Helios are shown. Cytokine and transcription factor staining were performed after cell permeabilization. Data are presented as mean � SEM; * p
< 0.05.

Conclusion
A diastereoselective synthesis of the cis,trans-configured perhydroquinoline-based KOR agonist (�)-4 was developed. Since
the racemate (�)-4 exhibited high KOR affinity (Ki = 1.2 nM),
enantiomerically pure KOR agonists 4 and ent-4 were synthesized by a lipase-catalyzed kinetic resolution of racemic alcohol
(�)-8. The 4aR,8S,8aS-configured ligand 4 represents the
eutomer with a KOR affinity of 0.81 nM. Moreover, 4 shows high
selectivity for KOR over MOR, DOR, σ1 and σ2 receptors. Whereas
4 has slightly lower KOR affinity than the prototypical KOR
agonist U-50,488, it shows higher KOR agonistic activity than U50,488 in the cAMP and β-arrestin-2 assay. A bias for the cAMP
or β-arrestin-2 pathway could not be observed.
The 4aR,8S,8aS-configured KOR agonist 4 showed strong
anti-inflammatory activity. After activation of human macrophages, human dendritic cells and mouse myeloid immune
cells, the number of cells expressing co-stimulatory receptor
CD86 and proinflammatory cytokines IL6 and TNF-α was
significantly reduced. The numbers of Th1 and Th17 cells was
significantly reduced by incubation of activated CD4 + T cells
ChemMedChem 2020, 15, 1408 – 1420
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with KOR agonist 4. Moreover, 4 led to downregulation of the
cytokine secretion and transcription factor expression (antiinflammatory activity), but did not induce immunomodulatory
effects. The enantiomerically pure KOR agonist 4 showed broad
and potent anti-inflammatory activity, but did not induce
immunomodulatory effects.
Very interestingly, all these different anti-inflammatory
effects correlate nicely with the KOR affinity of the KOR agonists
4, (�)-4, and ent-4. In general, the racemate (�)-4 was slightly
less potent than the eutomer 4 and the distomer ent-4 did not
exhibit anti-inflammatory effects.

Experimental Section
Chemistry, General Methods
Oxygen and moisture sensitive reactions were carried out under
nitrogen, dried with silica gel with moisture indicator (orange gel,
VWR, Darmstadt, Germany) and in dry glassware (Schlenk flask or
Schlenk tube). Thin layer chromatography (TLC): TLC silica gel 60
F254 on aluminum sheets (VWR). Flash chromatography (fc): Silica
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gel 60, 40–63 μm (VWR); parentheses include: diameter of the
column (∅), length of the stationary phase (l), fraction size (v) and
eluent. Melting point: Melting point system MP50 (Mettler Toledo,
Gießen, Germany), open capillary, uncorrected. MS: MicroTOFQII
mass spectrometer (Bruker Daltonics, Bremen, Germany); deviations
of the found exact masses from the calculated exact masses were
5 ppm or less; the data were analyzed with DataAnalysis® (Bruker
Daltonics). NMR: NMR spectra were recorded in deuterated solvents
on Agilent DD2 400 MHz and 600 MHz spectrometers (Agilent,
Santa Clara CA, USA); chemical shifts (δ) are reported in parts per
million (ppm) against the reference substance tetramethylsilane
and calculated from the solvent residual peak of the undeuterated
solvent; coupling constants are given with 0.5 Hz resolution;
assignment of 1H and 13C NMR signals was supported by 2-D NMR
techniques where necessary.IR: FT/IR IR Affinity®-1 spectrometer
(Shimadzu, Düsseldorf, Germany) using ATR technique. Optical
rotation: Polarimeter 341 (Perkin Elmer); 1.0 dm tube; concentration
c in g/100 mL; T = 20 °C; wavelength 589 nm (D-line of Na light); the
unit of the specific rotation ([α]TD grad mL dm 1.g 1) is omitted for
clarity. CD spectroscopy: Jasco (Pfungstadt, Germany) J-815 spectropolarimeter; concentration 1 mg/mL in acetonitrile.

HPLC methods
HPLC method 1 to determine the purity of compounds: Equipment
1: Pump: L-7100, degasser: L-7614, autosampler: L-7200, UV
detector: L-7400, interface: D-7000, data transfer: D-line, data
acquisition: HSM-Software (all from LaChrom, Merck Hitachi); Equipment 2: Pump: LPG-3400SD, degasser: DG-1210, autosampler: ACC3000T, UV detector: VWD-3400RS, interface: DIONEX UltiMate 3000,
data acquisition: Chromeleon 7 (Thermo Fisher Scientific); column:
LiChropher® 60 RP-select B (5 μm), LiChroCART® 250–4 mm cartridge; flow rate: 1.0 mL/min; injection volume: 5.0 μL; detection at
λ = 210 nm; solvents: A: demineralized water with 0.05 % (v/v)
trifluoroacetic acid, B: acetonitrile with 0.05 % (v/v) trifluoroacetic
acid; gradient elution (% A): 0–4 min: 90 %; 4–29 min: gradient from
90 to 0 %; 29–31 min: 0 %; 31–31.5 min: gradient from 0 to 90 %;
31.5–40 min: 90 %. The purity of all test compounds is greater than
95 %.
HPLC method 2 to determine the enantiomeric purity of alcohols
(R)-8 and (S)-8: Equipment: UV/Vis detector: L-7400, pump: L7150 A, autosampler: L-7200, data acquisition: HSM-software (LaChrom, Merck-Hitachi); column: Daicel Chiralpack® AD H
(250x4.6 mm, 5 μm particle size); flow rate: 1.0 mL min 1; injection
volume: 10 μL; detection at λ = 266 nm; solvent: isohexane/CH3OH
(95 : 5), isocratic.
HPLC method 3 to determine the enantiomeric purity of acetates
(R)-7 and (S)-7: Equipment: UV/Vis detector: L-7400, pump: L7150 A, autosampler: L-7200, data acquisition: HSM-software (LaChrom, Merck-Hitachi); column: Daicel Chiralpack® IA (250x4.6 mm,
5 μm particle size); flow rate: 1.0 mL min 1; injection volume: 10 μL;
detection at λ = 266 nm; solvent: isohexane/CH3OH (95 : 5), isocratic.
HPLC method 4 to determine the enantiomeric purity of KORagonists 4 and ent-4: Equipment: DAD detector: L-7455, pump: L6200 A, injector: Rheodyne 7725i, data acquisition: HSM-software
(LaChrom, Merck-Hitachi); column: Daicel Chiralpack® IA
(250x4.6 mm, 5 μm particle size); flow rate: 1.0 mL min 1; injection
volume: 5 μL; detection at λ = 275 nm; solvent: isohexane/isopropyl
alcohol (90 : 10) + 0.1 % diethylamine, isocratic.
HPLC method 5 to separate the KOR-agonists 4 and ent-4 on a
preparative scale: Equipment: UV/Vis detector: L-7400, pump: L7150A, autosampler: L-7200, data acquisition: HSM-software (LaChrom, Merck-Hitachi); column: Daicel Chiralpack® IA (250 × 20 mm,
5 μm particle size); flow rate: 15 mL min 1; injection volume: 400 μL;
ChemMedChem 2020, 15, 1408 – 1420
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detection at λ = 275 nm; solvent: isohexane/ ethanol (90 : 10) + 0.1 %
diethylamine, isocratic.

Synthetic procedures
(4aRS,8SR,8aSR)-8-(Pyrrolidin-1-yl)-decahydroquinoline[33] ((�)-13)
Pyrrolidine (0.34 mL, 4.14 mL, 6.0 equiv) was added to a solution of
(�)-12 (150 mg, 0.69 mmol, 1.0 equiv) in dry acetonitrile (1.5 mL).
After stirring for 18 h at 80 °C, additional pyrrolidine (0.17 mL,
2.07 mmol, 3.0 equiv) was added and the mixture was stirred for
another 2 h at 80 °C. The solvent was removed in vacuo, toluene
was added and evaporated in vacuo several times (azeotropic
evaporation of excess pyrrolidine). After addition of HCl (1 M, 1 mL),
the mixture was washed with Et2O (2 × 2 mL). The pH value of the
aqueous layer was then set to pH 10 by addition of NaOH (1 M,
1 mL) and extracted with Et2O (2 × 2 mL). After additional extraction
with EtOAc (5 × 2 mL) the combined organic layers were dried
(Na2SO4), filtered and evaporated in vacuo. The residue was purified
by flash column chromatography (d = 2 cm, h = 20 cm, V = 10 mL,
CH2Cl2/CH3OH (98 : 2!95 : 5) and then CH2Cl2/CH3OH/Et3N (94 : 5 : 1)),
Rf = 0.11 (CH2Cl2/CH3OH 95 : 5). Yellow viscous oil, yield 118 mg
(82 %). Chemical formula: C13H24N2 (208.35 g/mol).
(4aR,8S,8aS)-8-(Pyrrolidin-1-yl)-decahydroquinoline (13)
Oxathiazole 12 (188 mg, 0.97 mmol, 1.0 equiv) was treated with
pyrrolidine (0.64 mL, 7.79 mmol, 8.0 equiv) in CH3CN (2 mL) as
described for (�)-13. Dark yellow oil, yield 107 mg (53 %). Specific
rotation: [α]20
D = + 26.6 (c = 3.2 mg/mL, CH3OH).
(4aS,8R,8aR)-8-(Pyrrolidin-1-yl)-decahydroquinoline (ent-13)
Oxathiazole ent-12 (205 mg, 0.94 mmol, 1.0 equiv) was treated with
pyrrolidine (0.47 mL, 5.72 mmol, 6.1 equiv) in CH3CN (2 mL) as
described for (�)-13. Dark yellow oil, yield 90 mg (46 %). Specific
rotation: [α]20
D = 16.9 (c = 3.4 mg/mL, CH3OH).
2-(3,4-Dichlorophenyl)-1-[(4aRS,8SR,8aSR)-8-(pyrrolidin-1-yl)3,4,4a,5,6,7,8,8a-octahydroquinolin-1(2H)-yl]ethan-1-one[33] ((�)-4)
Ethyldiisopropylamine (0.09 mL, 0.53 mmol, 2.0 equiv) was added
to a solution of (�)-13 (57 mg, 0.27 mmol, 1.0 equiv) in dry CH2Cl2
(2.5 mL). 2-(3,4-Dichlorophenyl)acetyl chloride (122 mg, 0.55 mmol,
2.0 equiv) dissolved in dry CH2Cl2 (0.5 mL) was added dropwise at
0 °C. The mixture was stirred for 1 h at room temperature. After
addition of H2O (3.0 mL), the mixture was extracted with CH2Cl2 (3 ×
5 mL). The combined organic layers were dried (Na2SO4), filtered
and concentrated in vacuo. The residue was purified by flash
column chromatography (d = 1 cm, h = 15 cm, V = 5 mL, CH2Cl2/
CH3OH (95 : 5), Rf = 0.31 (CH2Cl2/CH3OH 95 : 5)). Yellow solid, mp
83 °C, yield 61 mg (56 %). Chemical formula: C21H28Cl2N2O (395.4 g/
mol).
2-(3,4-Dichlorophenyl)-1-[(4aR,8S,8aS)-8-(pyrrolidin-1-yl)3,4,4a,5,6,7,8,8a-octahydroquinolin-1(2H)-yl]ethan-1-one (4)
Secondary amine 4 (81 mg, 0.39 mmol, 1.0 equiv) was treated with
ethyldiisopropylamine (0.13 mL, 0.76 mmol, 1.9 equiv) and 2-(3,4dichlorophenyl)acetyl chloride (174 mg, 0.78 mmol, 2.0 equiv) in
dry CH2Cl2 (3 mL) as described for (�)-4. The product was obtained
as a yellow oil with a yield of 110 mg (71 %, 80.3 %ee (HPLC method
4)). Therefore, a purification by chiral HPLC (HPLC method 5) was
performed. Yellow oil, yield 63 mg (41 %). Purity (HPLC method 1):
96.8 % (tR = 18.96 min). Enantiomeric purity (HPLC, method 4):
99.8 % ee (tR = 7.15 min). Specific rotation: [α]20
D = 22.6 (c = 6.4 mg/
mL, CH3OH).
2-(3,4-Dichlorophenyl)-1-[(4aS,8R,8aR)-8-(pyrrolidin-1-yl)3,4,4a,5,6,7,8,8a-octahydroquinolin-1(2H)-yl]ethan-1-one (ent-4)
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Secondary amine ent-13 (67 mg, 0.32 mmol, 1.0 equiv) was treated
with ethyldiisopropylamine (0.11 mL, 0.65 mmol, 2.0 equiv) and 2(3,4-dichlorophenyl)acetyl chloride (144 mg, 0.64 mmol, 2.0 equiv)
in dry CH2Cl2 (3 mL) as described for (�)-4. The product was
obtained as a yellow oil with a yield of 71 mg (56 %, 66.3 % ee
(HPLC method 4)). Therefore, a purification by chiral HPLC (HPLC
method 5) was performed. Yellow oil, yield 37 mg (29 %). Purity
(HPLC method 1): 97.2 % (tR = 19.02 min). Enantiomeric purity (HPLC
method 4): 99.0 % ee (tR = 8.75 min). Specific rotation: [α]20
D = + 23.3
(c = 3.5 mg/mL, CH3OH).

Receptor binding studies
Materials
Guinea pig brains and rat brains were commercially available
(Harlan-Winkelmann, Borchen, Germany). Homogenizers: Elvehjem
Potter (B. Braun Biotech International, Melsungen, Germany) and
Soniprep® 150 (MSE, London, UK). Centrifuges: Cooling centrifuge
model Eppendorf 5427R (Eppendorf, Hamburg, Germany) and Highspeed cooling centrifuge model Sorvall® RC-5 C plus (Thermo Fisher
Scientific, Langenselbold, Germany). Multiplates: standard 96 well
multiplates (Diagonal, Muenster, Germany). Shaker: self-made
device with adjustable temperature and tumbling speed (scientific
workshop of the institute). Harvester: MicroBeta® FilterMate 96
Harvester. Filter: Printed Filtermat Typ A and B. Scintillator: Meltilex®
(Typ A or B) solid state scintillator. Scintillation analyzer: MicroBeta®
Trilux (all Perkin Elmer LAS, Rodgau-Jügesheim, Germany).

Preparation of membrane homogenates from guinea pig brain
Five guinea pig brains were homogenized with the potter (500–
800 rpm, 10 up and down strokes) in 6 volumes of cold 0.32 M
sucrose. The suspension was centrifuged at 1200 g for 10 min at
4 °C. The supernatant was separated and centrifuged at 23 500 g for
20 min at 4 °C. The pellet was resuspended in 5–6 volumes of buffer
(50 mM Tris, pH 7.4) and centrifuged again at 23 500 g (20 min, 4 °C).
This procedure was repeated twice. The final pellet was resuspended in 5–6 volumes of buffer and frozen ( 80 °C) in 1.5 mL
portions containing about 1.5 mg protein/mL.

Preparation of membrane homogenates from rat brain
Five rat brains (species: Sprague Dawley rats) were homogenized
with the potter (500–800 rpm, 10 up and down strokes) in 6
volumes of cold 0.32 M sucrose. The suspension was centrifuged at
1200 g for 10 min at 4 °C. The supernatant was separated and
centrifuged at 23 500 g for 20 min at 4 °C. The pellet was
resuspended in 5–6 volumes of buffer (50 mM Tris, pH 7.4) and
centrifuged again at 23 500 g (20 min, 4 °C). This procedure was
repeated twice. The final pellet was resuspended in 5–6 volumes of
buffer and frozen ( 80 °C) in 1.5 mL portions containing about
1.5 mg protein/mL.

Protein determination
The protein concentration was determined by the method of
Bradford,[34] modified by Stoscheck.[35] The Bradford solution was
prepared by dissolving 5 mg of Coomassie Brilliant Blue G 250 in
2.5 mL of EtOH (95 %, v/v). 10 mL deionized H2O and 5 mL
phosphoric acid (85 %, m/v) were added to this solution, the
mixture was stirred and filled to a total volume of 50 mL with
deionized water. The calibration was carried out using bovine
serum albumin as a standard in 9 concentrations (0.1, 0.2, 0.4, 0.6,
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0.8, 1.0, 1.5, 2.0 and 4.0 mg /mL). In a 96-well standard multiplate,
10 μL of the calibration solution or 10 μL of the membrane receptor
preparation were mixed with 190 μL of the Bradford solution,
respectively. After 5 min, the UV absorption of the protein-dye
complex at λ = 595 nm was measured with a plate reader (Tecan
Genios®, Tecan, Crailsheim, Germany).

General procedures for the binding assays
The test compound solutions were prepared by dissolving approximately 10 μmol (usually 2–4 mg) of test compound in DMSO so
that a 10 mM stock solution was obtained. To obtain the required
test solutions for the assay, the DMSO stock solution was diluted
with the respective assay buffer. The filter mats were presoaked in
0.5 % aqueous polyethylenimine solution for 2 h at RT before use.
All binding experiments were carried out in duplicates in the 96
well multiplates. The concentrations given are the final concentration in the assay. Generally, the assays were performed by
addition of 50 μL of the respective assay buffer, 50 μL of test
compound solution in various concentrations (10 5, 10 6, 10 7, 10 8,
10 9 and 10 10 mol/L), 50 μL of the corresponding radioligand
solution and 50 μL of the respective receptor preparation into each
well of the multiplate (total volume 200 μL). The receptor
preparation was always added last. During the incubation, the
multiplates were shaken at a speed of 500–600 rpm at the specified
temperature. Unless otherwise noted, the assays were terminated
after 120 min by rapid filtration using the harvester. During the
filtration, each well was washed five times with 300 μL of water.
Subsequently, the filter mats were dried at 95 °C. The solid
scintillator was melted on the dried filter mats at a temperature of
95 °C for 5 min. After solidifying of the scintillator at RT, the trapped
radioactivity in the filter mats was measured with the scintillation
analyzer. Each position on the filter mat corresponding to one well
of the multiplate was measured for 5 min with the [3H]-counting
protocol. The overall counting efficiency was 20 %. The IC50 values
were calculated with the program GraphPad Prism® 3.0 (GraphPad
Software) by nonlinear regression analysis. Subsequently, the IC50
values were transformed into Ki values using the equation of Cheng
and Prusoff.[36] The Ki values are given as mean value � SEM from
three independent experiments.

KOR assay
The assay was performed with the radioligand [3H]U-69,593 (55 Ci/
mmol, BIOTREND). The thawed guinea pig brain membrane
preparation (about 100 μg of the protein) was incubated with
various concentrations of test compounds, 1 nM [3H]U-69,593, and
Tris-MgCl2 buffer (50 mM Tris, 8 mM MgCl2, pH 7.4) at 37 °C. The
nonspecific binding was determined with 10 μM unlabeled U69,593. The Kd value of U-69,593 is 0.69 nM.[27]

MOR assay
The assay was performed with the radioligand [3H]DAMGO (51 Ci/
mmol, Perkin Elmer). The thawed guinea pig brain membrane
preparation (about 100 μg of the protein) was incubated with
various concentrations of test compounds, 3 nM [3H]DAMGO, and
Tris-MgCl2 buffer (50 mM Tris, 8 mM MgCl2, pH 7.4) at 37 °C. The
nonspecific binding was determined with 10 μM unlabeled naloxone. The Kd value of DAMGO is 0.57 nM.[26]
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DOR assay
3

The assay was performed with the radioligand [ H]DPDPE (69 Ci/
mmol, BIOTREND). The thawed rat brain membrane preparation
(about 75 μg of the protein) was incubated with various concentrations of test compounds, 3 nM [3H]DPDPE, and Tris-MgCl2 buffer
(50 mM Tris, 8 mM MgCl2, pH 7.4) supplemented with SIGMAFAST®
protease inhibitor mix (Sigma Aldrich Biochemicals, Hamburg,
Germany; 1 tablet dissolved in 100 mL of buffer) at 37 °C. The
nonspecific binding was determined with 10 μM unlabeled morphine. The Kd value of DPDPE is 0.65 nM.[25]

σ1 receptor assay
The assay was performed with the radioligand [3H]-(+)-Pentazocine
(22.0 Ci/mmol; Perkin Elmer). The thawed membrane preparation of
guinea pig brain cortex (about 100 μg of protein) was incubated
with various concentrations of test compounds, 2 nM [3H]-(+)-Pentazocine, and Tris buffer (50 mM, pH 7.4) at 37 °C. The nonspecific
binding was determined with 10 μM unlabeled (+)-Pentazocine.
The Kd value of (+)-Pentazocine is 2.9 nM.[37]

Immune cell isolation and multicolor flow cytometry
Purification and stimulation of mouse immune cell populations

σ2 receptor assay
The assays were performed with the radioligand [3H]DTG (specific
activity 50 Ci/mmol; ARC, St. Louis, MO, USA). The thawed
membrane preparation of rat liver (about 100 μg of protein) was
incubated with various concentrations of the test compound, 3 nM
[3H]DTG and buffer containing (+)-pentazocine (500 nM (+)-pentazocine in 50 mM Tris, pH 8.0) at room temperature. The nonspecific
binding was determined with 10 μM unlabeled DTG. The Kd value
of [3H]DTG is 17.9 nM.[38]

In vitro functional assays
cAMP inhibition assay
To measure KOR Gαi-mediated cAMP inhibition, HEK 293T (ATCC
CRL-11268) cells were co-transfected with human KOR along with a
luciferase-based cAMP biosensor (GloSensor; Promega) and assays
were performed similar to previously described.[39] After 16 h,
transfected cells were plated into Poly-lysine coated 384-well white
clear bottom cell culture plates with DMEM + 1 % dialyzed FBS at a
density of 15 000–20 000 cells per 40 μL per well and incubated at
37 °C with 5 % CO2 overnight. The next day, drug solutions were
prepared in fresh drug buffer (20 mM HEPES, 1 × HBSS, 0.3 % bovine
serum albumin (BSA), pH 7.4) at 3 × drug concentration. Plates were
decanted and received 20 μL per well of drug buffer (20 mM HEPES,
1 × HBSS) followed by addition of 10 μL of drug solution (3 wells
per condition) for 15 min in the dark at room temperature. To
stimulate endogenous cAMP via β adrenergic-Gs activation, 10 μL
luciferin (4 mM final concentration) supplemented with isoproterenol (400 nM final concentration) were added per well. Cells were
again incubated in the dark at room temperature for 15 min, and
luminescence intensity was quantified using a Wallac TriLux
microbeta (Perkin Elmer) luminescence counter. Results (relative
luminescence units) were plotted as a function of drug concentration, normalized to % SalA stimulation, and analyzed by using
“log(agonist) vs. response” in GraphPad Prism 5.0.

Tango β-arrestin-2 recruitment assay
The KOR Tango constructs were designed and assays were
performed as previously described.[40] HTLA cells expressing TEV

ChemMedChem 2020, 15, 1408 – 1420

fused-β-arrestin2 (kindly provided by Dr. Richard Axel, Columbia
University) were transfected with the KOR Tango construct. The
next day, cells were plated in DMEM supplemented with 1 %
dialyzed FBS in poly-L-lysine coated 384-well white clear bottom
cell culture plates at a density of 10 000–15 000 cells/well in a total
of 40 μL. The cells were incubated for at least 6 h before receiving
drug stimulation. Drug solutions were prepared in drug buffer
(20 mM HEPES, 1 × HBSS, 0.3 % BSA, pH 7.4) at 3 × and added to
cells (20 μL per well) for overnight incubation. Drug solutions used
for the Tango assay were exactly the same as used for the cAMP
assay. The next day, media and drug solutions were removed and
20 μL per well of BrightGlo reagent (purchased from Promega, after
1 : 20 dilution) was added. The plate was incubated for 20 min at
room temperature in the dark before being counted using a
luminescence counter. Results (relative luminescence units) were
plotted as a function of drug concentration, normalized to % SalA
stimulation, and analyzed using “log(agonist) vs. response” in
GraphPad Prism 5.0.

www.chemmedchem.org

C57BL/6 mice (wild-type, WT; purchased from Janvier Labs, Le
Genest-Saint-Isle, France) were used at the age of 8 to 12 weeks
and housed under specific pathogen–free (SPF) conditions in
microisolator cages. Mice were given chow and water ad libitum
and animal experiments were performed with the approval of the
State Review Board of North Rhine-Westphalia according to the
German law for animal welfare (reference number 81–
02.05.50.17.015). After sacrifice of mice spleen and peripheral lymph
nodes were removed to isolate T cells, macrophages or DC. For this
purpose, single cell suspensions of the tissues were prepared
according to standard methods. Subsequently, total T cells were
isolated from using the Pan T Cell Isolation Kit II, DC were purified
using the Pan Dendritic Cell Isolation Kit mouse, macrophages were
separated from single cell suspensions with anti-F4/80 microbeads
(all purchased from Miltenyi Biotech, Bergisch Gladbach, Germany),
activated, stimulated with the compounds (�)-4, 4 and ent-4, and
subjected to flow cytometry analyses (see below). After isolation,
mouse macrophages or DC were activated for 12 h with LPS
(10 μg/mL) and cultured for additional 48 h in the presence of
compounds (�)-4, 4 and ent-4 at indicated concentrations or PBS
as a control. Mouse T cells were activated with plate-bound antiCD3 and soluble anti-CD28 (clones 145–2 C11 and 37.51; 0.5 μg/mL
each antibody, both purchased from Biolegend, San Diego, CA).
Finally, cells were subjected to flow cytometry (see below).

Purification and stimulation of human immune cells
Human macrophages, DC and T cells were isolated from peripheral
blood mononuclear cells (PBMC). Therefore, PBMC were purified
from fully anonymized leukapheresis reduction chambers, obtained
from the blood bank with the informed consent of healthy donors
by Ficoll gradient centrifugation according to standard methods
(Ficoll reagent was purchased from Merck). Total macrophages, DC
or T cells were selected using CD14 microbeads (macrophages) or
negatively enriched using the Pan-DC Enrichment Kit or the Pan T
Cell Isolation Kit (Miltenyi Biotech). All experiments were carried out
according to the declaration of Helsinki and were approved by the
ethical committee of the University of Münster Medical School
(2008-180-f-S). After isolation, human macrophages or DC were
activated for 12 h with LPS (10 μg/mL) and cultured for additional
48 h in the presence of compounds (�)-4, 4 and ent-4 at indicated
concentrations or PBS. Human T cells were activated with plate-
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bound anti-CD3 and soluble anti-CD28 (clones UCHT1 and CD28.2;
1 μg/mL each antibody, both purchased from Biolegend, San Diego,
CA). Finally, cells were subjected to flow cytometry.

function[43] in Microsoft Excel over the corresponding rotatory
strength vectors (length). A width of the band at 1/e height of
0.15 eV was chosen. The final spectrum was obtained as a weighted
average of the spectra of two conformers according to the
calculated Boltzmann distribution, applying a blue-shift of 0.55 eV.

Multicolor flow cytometry analyses
The expression of cell surface and intracellular markers was
analyzed by multicolor flow cytometry on a GalliosTM flow
cytometer (Beckman Coulter) using the Kaluza software. For flow
cytometry, mouse cells were stained in PBS using antibodies
against CD4 (clone RM4-5), CD11b (clone M1/ 70), CD86 (clone
GL1), MHC II (major histocompatibility complex II; clone M5/114),
CD69 (clone H1.2F3), F4/80 (clone BM8), CD40 (clone 3/23), and
CD19 (clone 6D5; all purchased from Biolegend). Intracellular
staining of Foxp3 (clone FJK-16s), Helios (clone 22F6), IFN-γ (clone
XMG1.2), IL-12 (clone C17.8), IL-17 (clone TC11-18H10.0), ROR-γt
(clone REA278), T-bet (clone 4B10), IL-6 (clone MP5-20F3), and TNFα (clone MP6-XT22; all purchased from Biolegend or Miltenyi
Biotech) was performed after cell permeabilization using the Fix/
Perm Buffer Set (Biolegend) according to the manufacturer’s
instructions.
Human cells were stained in PBS using antibodies against CD4
(clone OKT4), CD11b (clone M1/ 70), CD86 (clone BU63), CD40
(clone 5 C3), and HLA-DR (clone L243; all purchased from
Biolegend). Intracellular staining of Foxp3 (clone 206D), Helios
(clone 22F6), IFN-γ (clone 4S.B3), IL-12 (clone C11.5), IL-17 (clone
BL168), ROR-c (clone REA278), T-bet (clone 4B10), IL-6 (clone MQ213 A5), and TNF-α (clone Mab11; all purchased from Biolegend or
Miltenyi Biotech) was performed after cell permeabilization using
the Fix/Perm Buffer Set (Biolegend) according to the manufacturer’s
instructions. Isotype-matched controls were included in each
staining, and apoptotic cells were identified using an annexin V
apoptosis detection kit.

The Supporting Information contains the scheme for the
synthesis of enantiomerically pure KOR agonists 4 and ent-4,
procedures and analytical data of synthesized compounds,
HPLC chromatograms of enantiomerically pure acetates 7,
alcohols 8 and KOR agonists 4, effects of (�)-4 on CD4 + T cells
and 1H and 13C NMR spectra of all prepared compounds.
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Statistics
All values are expressed as means � SEM. Statistically significant
differences were assessed by one-way analysis of variance (ANOVA)
test, comparing more than two groups. The alpha-level was set at a
value of < 0.05 in all cases. SigmaPlot 14 or GraphPad Prism 8 was
used to analyze, plot, and illustrate data.

Computational methods – Simulation of electronic CD spectra
A 3D molecular model of (S)-14 was built with the Molecular
Operating Environment (MOE) software (version 2018.0101).[41] The
structure was then energy minimized using the MMFF94x force
field. Compound (S)-14 was then subjected to a conformational
search using the low mode molecular dynamics (LowMD) method
and the MMFF94x force field, as implemented in MOE, with an
energy window of 5 kcal/mol. The structures of the generated
conformers (six low-energy conformers) were stepwise-optimized in
Gaussian 03.[42] During the first step, the AM1 semi-empirical
method was employed. Calculation at higher level of theory using
the B3LYP density functional and a 6–31G(d,p) basis set constituted
the second optimization step. The population of the resulting
conformers were calculated from their final total energies by a
Boltzmann distribution. TDDFT calculations were performed for the
first two conformers (representing 95 % of the population) using
the same density functional and basis set as above, considering the
30 lowest-energy electronic transitions for each conformer. All
calculations were run in vacuo. The ECD curve, expressed as the
differential molar extinction, Δɛ (in M 1 cm 1) as function of the
energy, E (in eV), was obtained by applying a Gaussian-type
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